Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.

about

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.

Item

http://www.wikidata.org/entity/Q49922743

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Beyond Second-Line Therapy in ...... l Cancer: A Systematic Review.

@nl

Beyond second-line therapy in ...... l cancer: a systematic review.

@en

type

Item

label

Beyond Second-Line Therapy in ...... l Cancer: A Systematic Review.

@nl

Beyond second-line therapy in ...... l cancer: a systematic review.

@en

prefLabel

Beyond Second-Line Therapy in ...... l Cancer: A Systematic Review.

@nl

Beyond second-line therapy in ...... l cancer: a systematic review.

@en

P1476

Beyond second-line therapy in ...... l cancer: a systematic review.

@en

P2093

A Quintela

http://www.w3.org/2001/XMLSchema#string

A Stein

http://www.w3.org/2001/XMLSchema#string

D Arnold

http://www.w3.org/2001/XMLSchema#string

G W Prager

http://www.w3.org/2001/XMLSchema#string

J Taieb

http://www.w3.org/2001/XMLSchema#string

N Mounedji

http://www.w3.org/2001/XMLSchema#string

S Moreno Vera

http://www.w3.org/2001/XMLSchema#string

P2860

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

P304

835-856

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDY038

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29452346

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5913602

http://www.w3.org/2001/XMLSchema#string